Table 5.
Change in percent (%) acute toxicity: Total group ➔ patients who received mitomycin-C (IMRT 75.4%; 3D-CRT 85.6%)
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | |||||
|---|---|---|---|---|---|---|---|---|
| IMRT | 3D-CRT | IMRT | 3D-CRT | IMRT | 3D-CRT | IMRT | 3D-CRT | |
| Localized pain | 41 ➔ 41.3 | 26.9 ➔ 29.2 | 32.8 ➔ 34.8 | 45.2 ➔ 43.8 | 3.3 ➔ 4.3 | 11.5 ➔ 12.4 | 0 | 1 ➔ 1.1 |
| Diarrhea | 31.1 ➔ 32.6 | 36.5 ➔ 38.2 | 23 ➔ 17.4 | 25 ➔ 25.8 | 6.6 ➔ 8.7 | 7.7 ➔ 7.9 | 0 | 1 ➔ 1.1 |
| Fatigue | 32.8 ➔ 32.6 | 30.8 ➔ 31.5 | 24.6 ➔ 21.7 | 22.1 ➔ 24.7 | 0 | 4.8 ➔ 2.2 | 0 | 0 |
| Dermatitis | 26.6 ➔ 23.9 | 21.2 ➔ 15.7 | 60.7 ➔ 65.2 | 55.8 ➔ 60.7 | 8.2 ➔ 10.9 | 18.3 ➔ 20.2 | 0 | 0 |
| Hematologic | 31.1 ➔ 32.6 | 41.3 ➔ 40.4 | 23 ➔ 21.7 | 23.1 ➔ 24.7 | 6.6 ➔ 6.5 | 14.4 ➔ 14.6 | 4.9 ➔ 6.5 | 3.8 ➔ 4.5 |
| Incontinence | 19.7 ➔ 23.9 | 28.8 ➔ 31.5 | 8.2 ➔ 6.5 | 15.4 ➔ 15.7 | 0 | 1.9 ➔ 2.2 | 0 | 1 ➔ 1.1 |
| Gastroenteritisa | 0 | 0 | 0 | 0 | 1 ➔ 2.2 | 1 ➔ 1.1 | 0 | 0 |
| Colitis | 0 | 0 | 0 | 0 | 0 | 1.9 ➔ 2.2 | 0 | 0 |
| Proctitis | 0 | 0 | 0 | 0 | 0 | 1 ➔ 1.1 | 0 | 0 |
| Fistula | 0 | 0 | 0 | 0 | 0 | 1.9 ➔ 1.1 | 0 | 0 |
| Stenosis | 0 | 0 | 0 | 0 | 0 | 1 ➔ 1.1 | 0 | 0 |
IMRT intensity-modulated radiation therapy, 3D-CRT 3-dimensional conventional radiation therapy
aFrom treatment completion through 8 weeks post treatment